^
    Apply
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    Fulvestrant With or Without Ganetespib in HR+ Breast Cancer (NCT01560416)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    05/01/2012
    Primary completion :
    06/01/2016
    Completion :
    12/01/2024
    HER-2 • PGR
    |
    HER-2 negative • PGR positive
    |
    fulvestrant • ganetespib (ADX-1612)
    STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer (NCT01167114)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    11/02/2023
    Initiation :
    08/01/2010
    Primary completion :
    05/01/2016
    Completion :
    04/01/2017
    HSP90AA1
    |
    ganetespib (ADX-1612)
    Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers (NCT01579994)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    12/30/2020
    Initiation :
    04/16/2012
    Primary completion :
    12/28/2020
    Completion :
    12/28/2020
    ALK
    |
    ALK positive • ALK rearrangement • ALK translocation
    |
    Xalkori (crizotinib) • ganetespib (ADX-1612)
    SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) (NCT02008877)
    Phase 1/2
    Sarcoma Alliance for Research through Collabora...
    Completed
    Last update posted :
    05/15/2019
    Initiation :
    12/01/2013
    Primary completion :
    04/01/2018
    Completion :
    07/01/2018
    NF1
    |
    Torisel (temsirolimus) • sirolimus • ganetespib (ADX-1612)
    STA-9090(Ganetespib) in Metastatic Ocular Melanoma (NCT01200238)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    10/18/2018
    Initiation :
    09/17/2010
    Primary completion :
    10/12/2014
    Completion :
    11/11/2016
    MET • HSP90AA1
    |
    MET expression
    |
    ganetespib (ADX-1612)
    Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (NCT02060253)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    06/14/2018
    Initiation :
    04/01/2014
    Primary completion :
    06/01/2018
    Completion :
    06/01/2018
    HER-2 • ER • PGR
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • ganetespib (ADX-1612)
    A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer (NCT02637375)
    Phase N/A
    University of Chicago
    Withdrawn
    Last update posted :
    05/30/2016
    Initiation :
    05/01/2016
    Primary completion :
    12/01/2018
    Completion :
    12/01/2018
    HER-2 • ER • PGR
    |
    HER-2 overexpression • ER negative • PGR negative
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide • ganetespib (ADX-1612)
    A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) (NCT01039519)
    Phase 2
    Synta Pharmaceuticals Corp.
    Completed
    Last update posted :
    03/10/2016
    Initiation :
    01/01/2010
    Primary completion :
    12/01/2011
    Completion :
    12/01/2011
    HSP90AA1
    |
    imatinib • sunitinib • ganetespib (ADX-1612)
    Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer (NCT01273896)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    11/20/2015
    Initiation :
    01/01/2011
    Primary completion :
    09/01/2013
    Completion :
    09/01/2013
    HER-2
    |
    ganetespib (ADX-1612)
    An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (Enchant) (NCT01677455)
    Phase 2
    Synta Pharmaceuticals Corp.
    Completed
    Last update posted :
    11/05/2015
    Initiation :
    07/01/2012
    Primary completion :
    04/01/2015
    Completion :
    08/01/2015
    HER-2
    |
    ganetespib (ADX-1612)
    A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) (NCT01562015)
    Phase 2
    Synta Pharmaceuticals Corp.
    Completed
    Last update posted :
    05/20/2015
    Initiation :
    04/01/2012
    Primary completion :
    08/01/2014
    Completion :
    11/01/2014
    ALK
    |
    ALK translocation
    |
    ganetespib (ADX-1612)